Edesa Biotech
EDSA
20 hedge funds and large institutions have $4.28M invested in Edesa Biotech in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 20 → 20 (0)
10.36% less ownership
Funds ownership: 40.38% → 30.02% (-10%)
38% less capital invested
Capital invested by funds: $6.89M → $4.28M (-$2.61M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$14.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.45K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.45K |
| 4 |
Morgan Stanley
New York
|
+$1.24K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$68 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.68M |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$48.8K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$31.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.16K |
EDSA Hedge Fund Activity: Q2 2025 in Review
20 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q2 2025, worth a combined $4.28M — down 38% from $6.89M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EDSA positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $14.7K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.68M sold.
- 20 institutional investors held Edesa Biotech (EDSA) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $4.28M of Edesa Biotech stock for Q2 2025, down 38% quarter-over-quarter.
- 4 funds opened new Edesa Biotech positions in Q2 2025 and 3 closed out, a net change of +1 holder.
- The largest Edesa Biotech buyer in Q2 2025 was Citadel Advisors, an estimated $14.7K added.
- The largest Edesa Biotech seller in Q2 2025 was Stonepine Capital Management, an estimated $1.68M sold.
Based on aggregated 13F filings for Q2 2025.